Elsevier acquires Windhover
This article was originally published in The Rose Sheet
Elsevier, the parent company of F-D-C Reports, builds upon its array of news and business intelligence services for drug and medical device industries with acquisition of Windhover Information, announced March 10. Elsevier says deal fits with its goal of increasing the "depth and breadth" of offerings that enable informed planning and strategic management. F-D-C Reports publications include "The Rose Sheet," "The Tan Sheet" and "The Pink Sheet," among others. Windhover's businesses include Strategic Transactions Database, a number of drug and device partnering and strategy conferences, and journals IN VIVO and RPM Report. Windhover will operate within Elsevier's Pharma Business Intelligence Unit, which includes Inteleos drug development database as well as F-D-C Reports...
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.